David Shapiro is a Gastroenterology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
676 N Saint Clair St Ste 1400
Chicago, IL 606112951
Telephone
312-695-4065Registry record last updated 4 Aug 2014.
Clinical trials
- Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Sponsor: Trinity Health Of New England
- Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
Sponsor: Intercept Pharmaceuticals
- Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)
Sponsor: Intercept Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IRONSHORE PHARMACEUTICALS INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
64.4%Proton pump inhibitor36.2%Omeprazole61%Pantoprazole Sodium29%Rabeprazole Sodium5%Lansoprazole5%Part D<11 patientsH2 blocker8.6%Famotidine100%Part D≥24 patients+ 6 more classes in this area
Blood & clotting
35.6%Solutions for parenteral nutrition35.6%Peg 3350-Electrolyte100%Part D≥291 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 1985–2025 per NIH RePORTER. The latest:
- A Pathway for Necrotic Cell Death
University of Illinois at Urbana-Champaign
FY2025$719,845R01CA265333 - A Pathway for Necrotic Cell Death
University of Illinois at Urbana-Champaign
FY2024$359,923R01CA265333 - A Pathway for Necrotic Cell Death
University of Illinois at Urbana-Champaign
FY2023$378,867R01CA265333
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”